Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 May 14;19(5):e0303599. doi: 10.1371/journal.pone.0303599

Mental-somatic multimorbidity in trajectories of cognitive function for middle-aged and older adults

Siting Chen 1, Corey L Nagel 2, Ruotong Liu 3, Anda Botoseneanu 4,5, Heather G Allore 6,7, Jason T Newsom 8, Stephen Thielke 9, Jeffrey Kaye 10, Ana R Quiñones 1,3,*
Editor: Bruno Pereira Nunes11
PMCID: PMC11093294  PMID: 38743678

Abstract

Introduction

Multimorbidity may confer higher risk for cognitive decline than any single constituent disease. This study aims to identify distinct trajectories of cognitive impairment probability among middle-aged and older adults, and to assess the effect of changes in mental-somatic multimorbidity on these distinct trajectories.

Methods

Data from the Health and Retirement Study (1998–2016) were employed to estimate group-based trajectory models identifying distinct trajectories of cognitive impairment probability. Four time-varying mental-somatic multimorbidity combinations (somatic, stroke, depressive, stroke and depressive) were examined for their association with observed trajectories of cognitive impairment probability with age. Multinomial logistic regression analysis was conducted to quantify the association of sociodemographic and health-related factors with trajectory group membership.

Results

Respondents (N = 20,070) had a mean age of 61.0 years (SD = 8.7) at baseline. Three distinct cognitive trajectories were identified using group-based trajectory modelling: (1) Low risk with late-life increase (62.6%), (2) Low initial risk with rapid increase (25.7%), and (3) High risk (11.7%). For adults following along Low risk with late-life increase, the odds of cognitive impairment for stroke and depressive multimorbidity (OR:3.92, 95%CI:2.91,5.28) were nearly two times higher than either stroke multimorbidity (OR:2.06, 95%CI:1.75,2.43) or depressive multimorbidity (OR:2.03, 95%CI:1.71,2.41). The odds of cognitive impairment for stroke and depressive multimorbidity in Low initial risk with rapid increase or High risk (OR:4.31, 95%CI:3.50,5.31; OR:3.43, 95%CI:2.07,5.66, respectively) were moderately higher than stroke multimorbidity (OR:2.71, 95%CI:2.35, 3.13; OR: 3.23, 95%CI:2.16, 4.81, respectively). In the multinomial logistic regression model, non-Hispanic Black and Hispanic respondents had higher odds of being in Low initial risk with rapid increase and High risk relative to non-Hispanic White adults.

Conclusions

These findings show that depressive and stroke multimorbidity combinations have the greatest association with rapid cognitive declines and their prevention may postpone these declines, especially in socially disadvantaged and minoritized groups.

1. Introduction

Cognitive decline is a prominent feature within the continuum of Alzheimer’s disease and related dementias (ADRD), and poses challenging and complex problems exerting considerable health, social, and psychological burdens on individuals, and high costs to societies [1, 2]. The efficacy of early interventions intended to delay cognitive decline resulting from the progression of ADRD is supported by existing evidence, although approved disease-modifying treatments are scarce [1]. Therefore, it is critical to identify potentially modifiable risk factors and to inform the development of feasible interventions for older adults that can be implemented during critical, transitional stages of cognitive decline [35].

Multimorbidity (≥2 chronic diseases) commonly occurs among older adults [6] and is associated with a higher risk of cognitive decline and ADRD [68]. However, many studies conceptualize multimorbidity as a count of chronic diseases or as a single summary index/score, making it difficult to assess the impact of specific combinations of diseases [911]. In addition, prior studies have largely been conducted using cross-sectional designs or with short follow-up periods, which precludes the identification of long-term associations between multimorbidity and cognitive trajectories [911].

More recent work examines specific multimorbidity combinations [8, 1216] to address questions regarding chronic disease contributions to adverse outcomes, including cognitive decline. The U.S. Department of Health and Human Services (HHS) outlined a conceptual framework for considering both somatic and mental health conditions in defining and measuring multimorbidity [17]. In particular, stroke represents one of the leading causes of cognitive impairment among adults with cardiometabolic conditions [18, 19], while depression, one of the most prevalent mental health disorders, may confer an increased risk of dementia [20, 21]. Several studies address the association between cardiometabolic multimorbidity—including stroke—as a critical component and cognitive decline [12, 14], and investigate the specific effect of depression on cognitive impairment in the context of co-existing morbidities [22, 23]. While these findings have shed light on possible shared mechanisms and pathways between multiple, co-occurring diseases that may contribute to the development of cognitive impairment, there is a paucity of research examining the combinations of diseases on cognitive impairment in comparison with either condition individually, or in the absence of both. Therefore, it is of considerable interest to examine mental-somatic multimorbidity profiles more broadly to elucidate differential associations with cognitive impairment.

The aim of this study is threefold. First, we identify and characterize distinct trajectories of the probability of cognitive impairment with advancing age among a large, nationally-representative cohort of middle-aged and older Americans. Second, we assess the differential association of changing morbidity profiles among four mental-somatic multimorbidity combination categories on the probability of cognitive impairment for each identified trajectory group. Third, we examine the sociodemographic and health-related characteristics associated with the probabilities of membership to each of the identified trajectory groups.

2. Materials and methods

2.1. Data source

The Health and Retirement Study (HRS) is an ongoing, nationally-representative longitudinal survey of noninstitutionalized Americans ages 51 and older. Interviews are conducted biennially to evaluate the health and economic standing of respondents toward the end of their work life and into retirement [24]. We used HRS survey waves 1998–2016 in this study to ensure measurement concordance. These data have been previously collected and are publicly available and, therefore, fully anonymized. The study protocol was approved by the Oregon Health and Science University Institutional Review Board under exemption category 4 (without need to obtain prior consent). The data were assessed from March 2022 to July 2023 for this current study.

2.2. Study population

The current study followed HRS participants from the earliest age of cohort eligibility until dropout or death. Of the 35,689 HRS respondents interviewed between 1998 and 2016 who were living in the community and cohort-eligible (i.e., respondents with a positive survey weight), we excluded 1,257 participants with proxy respondents due to missing assessment of depressive symptoms and 5,357 participants who reported other race or had missing data on any covariate or inconsistent reporting on chronic diseases after adjudication (i.e., “yes” followed by “no” at subsequent waves) [25]. Lastly, an additional 9,005 participants with fewer than 3 assessments of cognitive function and/or chronic diseases, as required for adequate modeling of temporal trajectories, were also excluded. The final analytic sample consisted of 20,070 respondents. The details of the study sample flow diagram are shown and described in S1 Fig in S1 Appendix.

2.3. Measures

2.3.1 Primary outcome: Cognitive impairment

Cognitive function was measured at each wave using the 27-point HRS cognitive scale [26, 27], a modified version of the Telephone Interview for Cognitive Status (TICS) [28]. This assessment includes 1) an immediate and delayed free recall test (range 0–20); 2) a serial sevens subtraction test (range 0–5); and 3) a counting backwards test (range 0–2). The summary cognitive function score across the composite subscales ranges between 0–27, with higher scores indicating better cognitive function. Consistent with Langa-Weir classification [29], the continuous score was categorized into three derived categories of cognitive function: normal (range 12–27), cognitively impaired but not demented (CIND) (range 7–11), and demented (range 0–6). For this analysis, we collapsed the CIND and demented categories to construct a binary indicator of normal versus impaired cognition.

2.3.2 Independent time-varying covariate:Mental-somatic multimorbidity combinations

Information on seven self-reported, physician-diagnosed chronic somatic conditions was collected at each interview: heart disease, hypertension, stroke (but not transient ischemic attack), diabetes, arthritis, lung disease, and cancer. These were assessed at baseline with, “Has a doctor ever told you that you have…?”, and at follow-up waves with, “Since we last talked with you, has a doctor told you that you have…?”. Depressive symptoms were measured at each wave using the 8-item Centers for Epidemiologic Research Depression (Center for Epidemiological Studies-Depression scale [CES-D 8]) scale [30, 31]. Respondents with four or more symptoms were defined as having high depressive symptoms [32].

Chronic disease multimorbidity was modeled as a time-varying variable, categorized at each wave as no multimorbidity (no or only one disease) or one of four mutually-exclusive multimorbidity combinations: 1) somatic multimorbidity excluding stroke (≥2 diseases: heart disease, lung disease, hypertension, arthritis, diabetes, cancer); 2) stroke multimorbidity (stroke and ≥1 somatic disease); 3) depressive multimorbidity (high depressive symptoms and ≥1 somatic disease excluding stroke); 4) stroke and depressive multimorbidity (both stroke and high depressive symptoms with/without any other somatic disease that may be present). These multimorbidity combinations were included in the model as time-varying covariates, such that participants could accumulate conditions and advance to a higher multimorbidity category (e.g., from stroke multimorbidity to stroke and depressive multimorbidity) or could revert to a lower multimorbidity category due to lower depressive symptoms in the subsequent waves.

2.3.3 Covariates

The following sociodemographic and health-related covariates were measured at the baseline interview: race/ethnicity (mutually exclusive categories: non-Hispanic White, non-Hispanic Black, Hispanic); sex (female/male); highest education (<high school, high school graduate, some college or ≥college graduate); household wealth (quartiles derived from baseline net worth in US dollars); smoking status (current, past, never smoker), and body mass index (BMI) category (underweight, healthy weight, overweight, obese). Specifically, race/ethnicity was defined using the two following questions: 1) “Do you consider yourself Hispanic or Latino?” and 2) “Do you consider yourself primarily white or Caucasian, Black or African American, American Indian, or Asian, or something else?” If the respondent identified as Hispanic, this would be prioritized over any other racial categories and the respondent would be categorized as Hispanic. Three mutually-exclusive groups were constructed for the analyses: non-Hispanic white, non-Hispanic black, and Hispanic. The BMI categories were defined as underweight (BMI<18.5), healthy weight (BMI = 18.5 to <25.0), overweight (BMI = 25 to <30.0), and obese (BMI ≥30) [33].

2.4. Statistical analysis

2.4.1 Trajectories of cognitive impairment and model selection

Group-based trajectory modeling (GBTM) is a semi-parametric, finite mixture modeling approach that uses maximum likelihood estimation to identify groups of individuals following trajectories of a similar pattern [34]. Centered age was the time metric for our analysis. We selected a logit link for GBTMs given the binary outcome, resulting in trajectories that represent the predicted probability of cognitive impairment with advancing age for each identified group. Following established guidance [35], we began by fitting a sequence of unconditional GBTMs in order to 1) determine the optimal number of trajectory groups and 2) select the most appropriate functional form (intercept only, linear, quadratic, or cubic) of each trajectory group. Model selection was an iterative process based on a combination of following criteria[35]: 1) diagnostic assessments including reduction in Bayesian Information Criterion (BIC), average posterior probability of group membership > 80% for all groups, odds of correct classification >5.0; 2) size of the smallest group >10% of total sample; and 3) the ability to capture clinically relevant and distinct trajectories of cognitive impairment risk across the entire observed age span. Based on these criteria, we opted for the three-group model as the best solution. Detailed modeling processes, diagnostic statistics and trajectory plots are shown in S2 Table in S1 Appendix and S2 Fig in S1 Appendix.

2.4.2 Estimated trajectories of cognitive impairment probability with transition between multimorbidity combination groups

After selecting the three-group model, we included time-varying indicators for multimorbidity combination groups to examine their association with the observed trajectory within each trajectory group while adjusting for baseline age. Additionally, to minimize bias from loss to follow-up, we adjusted for nonrandom participant attrition after three survey waves and conducted sensitivity analyses between models with and without accounting for missing data due to attrition [36] (details provided in S3-S5 Tables in S1 Appendix, S3 Fig in S1 Appendix). This full model provided group-specific estimates of whether time-varying multimorbidity combinations were associated with the course of the probability of cognitive impairment with advancing age.

Moreover, changes in multimorbidity combinations (e.g., transitioning from somatic multimorbidity to stroke multimorbidity) may have differential associations with the cognitive impairment probability across the age span. To examine these transitions, we fit models simulating transition between multimorbidity combinations at pre-specified ages. Specifically, we compared the predicted trajectories of cognitive impairment probability between respondents who transitioned from somatic multimorbidity to stroke multimorbidity, depressive multimorbidity, or stroke and depressive multimorbidity at decades of age (60,70,80 years) vs. those with consistent somatic multimorbidity (i.e., combinations that did not involve stroke or depressive symptoms) with advancing age.

2.4.3 Multinomial regression models: Sociodemographic and health-related covariates of trajectory group membership

Based on the full GBTM accounting for time-varying multimorbidity combinations and attrition, we assigned each respondent to a trajectory group for which they had the maximum posterior probability of membership. Descriptive methods were used to summarize characteristics by trajectory group membership: frequencies and percentages were calculated for categorical variables while means and standard deviations were calculated for continuous variables. Additionally, we performed chi-square tests and ANOVA tests to compare the characteristics between trajectory groups. We then conducted a separate multinomial logistic regression analysis to assess the association of sociodemographic and health-related covariates with trajectory group membership. The full multinomial logistic regression model was adjusted for baseline age, race/ethnicity, sex, education, wealth, smoking, and BMI categories. Two-way and three-way interaction terms between covariates were tested in the models. We constructed an additional multinomial logistic regression model with a person’s posterior probability of group membership as weights in a sensitivity analysis (See S6 Table in S1 Appendix).

All statistical analyses were performed in STATA/SE 16.1 and GBTMs were fit using the ‘traj’ package [37]. Data visualizations of trajectories were performed in R 3.6.2. A statistically significant level was set at p<0.05. Full and complete details of our methodological procedures are provided in the S1 Appendix. Technical details of the statistical procedures and codes for visualizing cognitive impairment trajectories are included in S2 Appendix.

3. Results

3.1. Sample characteristics

The analytic sample consisted of 20,070 respondents with a mean age of 61.0 years (SD = 8.7) at the baseline interview (Table 1). 57.5% of the study sample were female and 42.5% were male. Most respondents were non-Hispanic White (70.0%). Table 1 provides detailed descriptive information on the analytic sample at baseline. We provided an additional table presenting the distribution of trajectory groups by covariates in S1 Table in S1 Appendix.

Table 1. General characteristics of study population at baseline interview, Health and Retirement Study (1998–2016).

Total Low risk with late-life increase Low initial risk with rapid increase High risk p value
N (%) 20070 12560 (62.6) 5155 (25.7) 2355 (11.7)
Baseline age (mean (SD)) 61.0 (8.7) 60.3 (8.5) 62.9 (9.1) 60.7 (7.9) <0.01
Sex, n (%) <0.01
Male 8522 (42.5) 5222 (41.6) 2221 (43.1) 1079 (45.8)
Female 11548 (57.5) 7338 (58.4) 2934 (56.9) 1276 (54.2)
Race/ethnicity, n (%) <0.01
Hispanic 2320 (11.6) 1032 (8.2) 710 (13.8) 578 (24.5)
NH White 14046 (70.0) 10042 (80.0) 3234 (62.7) 770 (32.7)
NH Black 3704 (18.5) 1486 (11.8) 1211 (23.5) 1007 (42.8)
Education, n (%) <0.01
< High school 4166 (20.8) 1242 (9.9) 1533 (29.7) 1391 (59.1)
High school graduate 10566 (52.6) 6863 (54.6) 2864 (55.6) 839 (35.6)
College 5338 (26.6) 4455 (35.5) 758 (14.7) 125 (5.3)
Wealth quartiles a , n (%) <0.01
1st quartile (lowest) 5462 (27.2) 2472 (19.7) 1643 (31.9) 1347 (57.2)
2nd quartile 4922 (24.5) 2861 (22.8) 1515 (29.4) 546 (23.2)
3rd quartile 4877 (24.3) 3416 (27.2) 1143 (22.2) 318 (13.5)
4th quartile (highest) 4809 (24.0) 3811 (30.3) 854 (16.6) 144 (6.1)
Smoking, n (%) <0.01
Never smoker 8468 (42.2) 5511 (43.9) 2058 (39.9) 899 (38.2)
Past smoker 7797 (38.8) 4976 (39.6) 1993 (38.7) 828 (35.2)
Current smoker 3805 (19.0) 2073 (16.5) 1104 (21.4) 628 (26.7)
BMI categories, n (%) <0.01
Underweight 204 (1.0) 125 (1.0) 53 (1.0) 26 (1.1)
Normal weight 5854 (29.2) 3770 (30.0) 1462 (28.4) 622 (26.4)
Overweight 7874 (39.2) 4995 (39.8) 1998 (38.8) 881 (37.4)
Obese 6138 (30.6) 3670 (29.2) 1642 (31.9) 826 (35.1)
No. of chronic conditions, mean (SD) 1.5 (1.3) 1.4 (1.2) 1.8 (1.4) 1.9 (1.5) <0.01
Multimorbidity, n (%) <0.01
No multimorbidity 11134 (55.5) 7561 (60.2) 2471 (47.9) 1102 (46.8)
Somatic multimorbidity 6245 (31.1) 3784 (30.1) 1756 (34.1) 705 (29.9)
Stroke multimorbidity 537 (2.7) 291 (2.3) 178 (3.5) 68 (2.9)
Depressive multimorbidity 1959 (9.8) 860 (6.8) 658 (12.8) 441 (18.7)
Stroke and Depressive multimorbidity 195 (1.0) 64 (0.5) 92 (1.8) 39 (1.7)
Cognitive Score, mean (SD) 16.1 (4.3) 17.9 (3.1) 14.3 (3.8) 9.9 (3.5) <0.01
Cognition category, n (%) <0.01
Normal 17057 (85.0) 12446 (99.1) 3995 (77.5) 616 (26.2)
Cognitive impairment (CIND or demented) 3013 (15.0) 114 (0.9) 1160 (22.5) 1739 (73.8)
Attrition, n (%) <0.01
No attrition 12198 (60.8) 8120 (64.6) 2752 (53.4) 1326 (56.3)
Attrition 7872 (39.2) 4440 (35.4) 2403 (46.6) 1029 (43.7)

Abbreviations: NH = non-Hispanic; BMI: body mass index; CIND: cognitively impaired but not demented.

aQuartiles for wealth were derived from baseline net worth in US dollars.

Note: Group membership is assigned for each participant based on the maximum posterior probability from the full group-based trajectory model (with time-varying multimorbidity, adjusted or baseline age, and accounting for attrition). Chi-square tests were performed for categorical variables. ANOVA tests were performed for continuous variables.

3.2. Cognitive impairment trajectories

Fig 1 displays the three distinct trajectories of cognitive impairment probability in the unconditional GBTM without inclusion of time-varying multimorbidity indicators: Low risk with late-life increase, Low initial risk with rapid increase, and High risk. Specifically, the Low risk with late-life increase trajectory (63.7%), which represented the largest proportion of the study sample, displayed a low probability of cognitive impairment at ages 51–70 and exhibited a slowly increasing probability after age 70. However, Low initial risk with rapid increase (24.5%) started with a minimal probability of cognitive impairment at baseline age but experienced a rapid increase in the probability of impairment after age 60. Unlike the other two trajectories, High risk (11.8%) started, on average, with a high baseline probability of cognitive impairment and showed a steady increase throughout later ages.

Fig 1. Predicted probability of cognitive impairment in the unconditional group-based trajectory model.

Fig 1

Group membership is assigned for each participant based on maximum posterior probability rule from the unconditional group-based trajectory model (without time-varying multimorbidity, not accounting for attrition). Confidence bands represent 95% CIs of predicted probabilities.

3.3. Time-varying multimorbidity combinations and impact on developmental trajectories of cognitive impairment probability

Table 2 presents the group-specific estimates of the association between multimorbidity combinations and observed trajectories of cognitive impairment probability in the full model. In Low risk with late-life increase, stroke multimorbidity (OR: 2.06; 95%CI: 1.75, 2.43) and depressive multimorbidity (OR: 2.03; 95%CI: 1.71, 2.41) had similar higher odds of cognitive impairment relative to somatic multimorbidity. However, the odds of cognitive impairment for stroke and depressive multimorbidity (OR: 3.92; 95%CI: 2.91, 5.28) were nearly two times higher than either stroke multimorbidity or depressive multimorbidity. In Low initial risk with rapid increase and High risk, the odds of cognitive impairment were highest for stroke and depressive multimorbidity relative to somatic multimorbidity, although the odds for stroke multimorbidity (OR: 3.23; 95%CI: 2.16, 4.81) are similar to stroke and depressive multimorbidity (OR: 3.43; 95%CI: 2.07, 5.66) in the High risk trajectory.

Table 2. Odds of cognitive impairment by multimorbidity category in the full group-based trajectory model.

Low risk with late-life increase Low initial risk with rapid increase High risk
OR (95% CI) OR (95% CI) OR (95% CI)
Multimorbidity
Somatic multimorbidity Reference Reference Reference
No multimorbidity 0.75 (0.64, 0.88)** 0.68 (0.62, 0.74)** 0.74 (0.65, 0.85)**
Stroke multimorbidity 2.06 (1.75, 2.43)** 2.71 (2.35, 3.13)** 3.23 (2.16, 4.81)**
Depressive multimorbidity 2.03 (1.71, 2.41)** 1.89 (1.71, 2.10)** 1.70 (1.45, 2.00)**
Stroke and depressive multimorbidity 3.92 (2.91, 5.28)** 4.31 (3.50, 5.31)** 3.43 (2.07, 5.66)**

**p<0.01

3.4. Predicted trajectories of cognitive impairment probability with multimorbidity transition at pre-specified ages

GBTMs were constructed to estimate discontinuous changes in cognitive impairment probability associated with multimorbidity transitions at pre-specified ages. Fig 2 shows the predicted trajectories of cognitive impairment probability for respondents who transitioned from somatic multimorbidity to stroke/depressive/stroke and depressive multimorbidity (dashed lines) at decades of age (60, 70, 80 years) and respondents with consistent somatic multimorbidity with advancing age (reference group, solid lines). In Low risk with late-life increase, respondents who developed stroke and depressive multimorbidity in later life (age 80) experienced a moderate increase in the probability of impairment relative to somatic multimorbidity. Unlike the course observed in Low risk with late-life increase, relative to respondents with somatic multimorbidity, respondents developing stroke and depressive multimorbidity at ages 60, 70 and 80 exhibited significant increases in the probability of cognitive impairment in the Low initial risk with rapid increase and High risk trajectories. Specifically, Low initial risk with rapid increase showed a large increase in probability of cognitive impairment when transitioning from somatic multimorbidity to stroke/depressive/stroke and depressive multimorbidity. Group-specific estimates of cognitive impairment probabilities by multimorbidity groups were provided in S7 Table in S1 Appendix.

Fig 2. Predicted probability of cognitive impairment with multimorbidity transition at pre-specified ages in the full group-based trajectory model.

Fig 2

Predicted trajectories in respondents who transitioned from somatic multimorbidity (solid lines) to stroke multimorbidity/depressive multimorbidity/stroke and depressive multimorbidity (dashed lines) at decades of age (60/70/80 years) were shown. Solid lines over the observed age span represent predicted trajectories in respondents with consistent somatic multimorbidity with advancing age. Group membership is assigned for each participant based on maximum posterior probability rule from the full group-based trajectory model (with time-varying multimorbidity, accounting for attrition). Confidence bands represent 95% CIs of predicted probabilities.

3.5. Multinomial regression models: socio-demographic and health-related covariates associated with trajectory group membership

In the multinomial logistic regression model with covariates (Table 3), non-Hispanic Black and Hispanic respondents had higher odds of being in Low initial risk with rapid increase (non-Hispanic Black: OR: 2.42, 95%CI: 2.19, 2.66; Hispanic: OR: 1.59, 95%CI: 1.42, 1.79) and High risk (non-Hispanic Black: OR: 6.17, 95%CI: 5.43, 7.01; Hispanic: OR: 2.81, 95%CI: 2.42, 3.26) relative to non-Hispanic White respondents. Similarly, respondents with less than a high school education and lowest wealth quartile were more likely to be in these two groups. Female respondents were less likely to be in these two groups. Current smokers were more likely to be in Low initial risk with rapid increase. Overweight and obese categories were associated with lower odds of being in High risk.

Table 3. Sociodemographic and health-related covariates of trajectory group membership in the multinomial logistic regression model.

Low initial risk with rapid increase High risk
Characteristics OR (95% CI) OR (95% CI)
Race/ethnicity
Non-Hispanic White Reference Reference
Non-Hispanic Black 2.42(2.19,2.66) ** 6.17(5.43,7.01) **
Hispanic 1.59(1.42,1.79) ** 2.81(2.42,3.26) **
Sex
Male Reference Reference
Female 0.81(0.76,0.88) ** 0.64(0.58,0.72) **
Education
High School Graduate Reference Reference
<High School 2.29(2.09,2.51) ** 6.57(5.84,7.39) **
College 0.47(0.43,0.52) ** 0.27(0.22,0.33) **
Wealth quartiles
4th quartile (highest) Reference Reference
3rd quartile 1.19(1.07,1.32) ** 1.49(1.20,1.84) **
2nd quartile 1.52(1.36,1.68) ** 1.79(1.46,2.20) **
1st quartile (lowest) 1.66(1.48,1.85)** 3.31(2.71,4.05) **
Smoking
Never smoker Reference Reference
Past smoker 0.99(0.92,1.07) 0.93(0.82,1.05)
Current smoker 1.24(1.13,1.37) ** 1.13(0.99,1.30)
BMI categories, n (%)
Normal weight Reference Reference
Underweight 0.91(0.65,1.29) 0.98(0.59,1.61)
Overweight 0.94(0.86,1.02) 0.80(0.70,0.91)**
Obese 1.00(0.91,1.10) 0.78(0.68,0.89)**

Note: Reference group is Low risk with late-life increase. The model is adjusted for baseline age. Group membership is assigned for each participant based on their maximum posterior probability from the full group-based trajectory model (with time-varying multimorbidity, adjusted for baseline age and accounting for attrition).

**p<0.01

4. Discussion

This longitudinal study of a nationally-representative cohort of adults aged 51 years and older identified three distinct trajectories of the probability of cognitive impairment and quantified the associations of transitions between somatic, mental, and combined mental-somatic multimorbidity with the identified cognitive trajectories. The Low risk with late-life increase trajectory exhibited stable and preserved cognitive function with age, demonstrating a slight increase in the probability of cognitive impairment after age 80. The Low initial risk with rapid increase trajectory exhibited a sharp increase in the probability of impaired cognition from age 70 onward. In contrast to the other two groups, the High risk trajectory had high probability of cognitive impairment throughout the ages observed. Interestingly, we noted that transitioning to various mental-somatic multimorbidity combinations at different decades of advancing age might be associated with trajectories of cognitive impairment probabilities, with varying degrees of increased risk of cognitive impairment for each trajectory group.

Most notably, our findings indicated that the transition to stroke and depressive multimorbidity was related to the largest upward shift in each identified trajectory compared with transitioning to either stroke or depressive multimorbidity. The observed detrimental joint association of stroke and high depressive symptoms with cognitive decline might be attributed to shared biological abnormalities in the brain resulting from both stroke and depression with a reciprocal relationship [38]: structural changes caused by depression may accelerate the progression of vascular and Alzheimer’s neuropathological changes, and conversely, progression of vascular damage in brain may mediate the development of depression. Psychological pathways, such as exposure to stressful life events [39], may also serve as shared mechanisms underlying the impact of depression and stroke on cognition. Furthermore, there are interesting nuances between the three identified trajectories and the consequences of experiencing mental-somatic multimorbidity at different decades of late life. In the trajectories characterized by rapidly increasing cognitive impairment risk (Low initial risk with rapid increase) or sustained High risk in mid-life, onset of stroke multimorbidity accounts for much of the increase in risk of cognitive impairment. For adults following along the best performing trajectory (Low risk with late-life increase), the increased risk of cognitive impairment appears to be equivalent when transitioning to stroke/depressive/stroke and depressive multimorbidity, although stroke and depressive multimorbidity has a greater association with the risk of cognitive impairment in late life.

Understanding the heterogeneity among identified cognitive trajectories may aid in understanding characteristics associated with the course of cognitive decline. The multinomial regression model findings suggesting that racial/ethnic disparities and variation in educational attainment may differentially contribute to cognitive outcomes among older adults were consistent with existing literature [40, 41]. The highest odds of being in the High risk trajectory observed for minoritized adults and adults with less than a high school education suggests that persistently worse cognitive function might be partially explained by systemic and structural disparities and inequities imposed by social and environmental factors starting from early life [42, 43]. The Low initial risk with rapid increase trajectory was also found to be associated with individuals from Black and Hispanic backgrounds, social disadvantages from having lower wealth, and being less educated, indicating that the acceleration of cognitive change in the trajectory might be associated with a number of factors, such as less resilience to age-related changes in health, and diminished ability to tap into protective socio-economic resources as a result of lower wealth streams and educational inequities earlier in life. Collectively, these findings demonstrate that adults with lower wealth, lower educational background and minoritized groups may be more susceptible to somatic-mental multimorbidity-related cognitive impairment pathways, and add to existing literature by examining this extended association over a substantial period throughout middle and late life. However, we found that adults with obesity and overweight status had a lower likelihood to be a member in the High risk trajectory, indicating a potential protective effect of higher BMI on cognitive decline, which was also observed in other published research [4446]. This “paradox” is possibly attributable to better nutritional status [47] and lower expression and deposition of AD-related biomarkers such as Aβ [46] in higher BMI groups. Moreover, the physical activity theory supports that people with obesity are more inclined to perform physical activities that can help protect cognitive function in later life [48].

Consistent with our findings, several studies investigating heterogeneity of cognitive trajectories in U.S. population across a variety of data sources [49] identified a number of trajectory groups with similar distinct courses [4953]. Considering the high prevalence of multimorbidity among adults at increased risk for dementia, it is noteworthy that specific combinations of multimorbidity may be differentially associated with cognitive decline [12]. Chen et.al (2022) evaluated the association of multimorbidity burden and developmental trajectories of later-life dementia [54] and found that higher multimorbidity burden at baseline and rapid growth in the number of chronic conditions was associated with higher risk of dementia. Our study corroborates and adds to these findings by quantifying the role of stroke and depressive symptoms in the context of multimorbidity. Importantly, rather than evaluating multimorbidity and dementia in two separate periods of time, our study identifies distinct cognitive courses by applying the group based trajectory modeling approach to estimate contemporaneous changes in multimorbidity profiles and their associations with cognition from mid to late life.

Our study has several strengths. First, the HRS provides large, rich, and longitudinal survey data that enables us to model progression of cognitive impairment over an extended period, starting in middle age and into late life. Second, the prospective design and modeling approach with time-varying covariates allows us to evaluate changes in mental-somatic multimorbidity combinations and estimate associated probabilities of cognitive impairment. Third, our study adds to the emerging literature by examining the development of clinically meaningful mental-somatic multimorbidity combinations and its associations with risk of cognitive impairment over a substantial period in mid and late life.

A few limitations should also be noted. First, the physician-diagnosed chronic condition data are self-reported, and those reporting a stroke would have been survivors. Additionally, HRS collected depressive symptoms and not clinically diagnosed depression and its various subtypes. Similarly, cognitive function is measured with the validated TICS assessment instead of clinically diagnosed dementia. However, several studies have demonstrated concordance between respondent reports of conditions and ascertained disease diagnosis from other resources [55]. Second, given the long observation period in HRS design, the survival bias should be noted in the analyses. To mitigate the potential bias due to healthy survivorship, we extended the GBTM model to account for nonrandom attrition and conducted sensitivity analysis. Finally, while it is imperative to study multimorbidity in diverse samples of adults, we were limited by the number of racial and ethnic categories assessed in the HRS. Future studies should examine the risk of dementia associated with mental and somatic multimorbidity changes among even broader numbers of underrepresented racial and ethnic groups using data sources that facilitate these analyses.

Our study has important implications. We found that development of mental-somatic multimorbidity combinations with both high depressive symptoms and stroke is highly associated with higher probability of cognitive impairment during critical periods of mid to late adulthood. Our study illustrates the importance of specific and targeted efforts for screening for, preventing and treating stroke and depression, and highlights the potential benefits of more tailored interventions particularly in mid-life, as such efforts may contribute to delaying the cognitive decline and reducing the associated personal, societal and informal care burdens and costs of cognitive impairment.

Supporting information

S1 Appendix. Comprehensive analysis documentation.

(DOCX)

pone.0303599.s001.docx (194.9KB, docx)
S2 Appendix. Technical details and reproducible codes for visualization of cognitive impairment trajectories with multimorbidity transition.

(DOCX)

pone.0303599.s002.docx (24KB, docx)

Data Availability

The data underlying the results presented in this study are publicly available from the Health and Retirement Study, http://hrsonline.isr.umich.edu/. All analytic data files are available from the Figshare database (accession number(s) https://doi.org/10.6084/m9.figshare.25631778.v1).

Funding Statement

This work was supported by the National Institute on Aging at the National Institutes of Health (grant numbers RF1AG058545 to ARQ; HGA who contributed from the Yale Claude D. Pepper Older Americans Independence Center P30AG021342 and Yale Alzheimer's Disease Research Center P30AG066508; P30AG066518, and P30AG024978 to JK). Content is solely the responsibility of the authors and does not necessarily represent official views of the National Institutes of Health. The funders played no role in the design, execution, analysis, or interpretation of the data or writing of the study.

References

  • 1.2022 Alzheimer’s disease facts and figures. Alzheimers Dement. 2022;18(4):700–89. doi: 10.1002/alz.12638 [DOI] [PubMed] [Google Scholar]
  • 2.Aranda MP, Kremer IN, Hinton L, Zissimopoulos J, Whitmer RA, Hummel CH, et al. Impact of dementia: Health disparities, population trends, care interventions, and economic costs. J Am Geriatr Soc. 2021;69(7):1774–83. doi: 10.1111/jgs.17345 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement. 2015;11(6):718–26. doi: 10.1016/j.jalz.2015.05.016 [DOI] [PubMed] [Google Scholar]
  • 4.Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020;5(12):e661–e71. doi: 10.1016/S2468-2667(20)30185-7 [DOI] [PubMed] [Google Scholar]
  • 5.Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention. J Prev Alzheimers Dis. 2021;8(3):313–21. doi: 10.14283/jpad.2021.15 [DOI] [PubMed] [Google Scholar]
  • 6.Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9. doi: 10.1016/j.arr.2011.03.003 [DOI] [PubMed] [Google Scholar]
  • 7.Wei MY, Mukamal KJ. Multimorbidity and Mental Health-Related Quality of Life and Risk of Completed Suicide. J Am Geriatr Soc. 2019;67(3):511–9. doi: 10.1111/jgs.15678 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Quinones AR, Markwardt S, Botoseneanu A. Multimorbidity Combinations and Disability in Older Adults. J Gerontol A Biol Sci Med Sci. 2016;71(6):823–30. doi: 10.1093/gerona/glw035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kao SL, Wang JH, Chen SC, Li YY, Yang YL, Lo RY. Impact of Comorbidity Burden on Cognitive Decline: A Prospective Cohort Study of Older Adults with Dementia. Dement Geriatr Cogn Disord. 2021;50(1):43–50. doi: 10.1159/000514651 [DOI] [PubMed] [Google Scholar]
  • 10.Fabbri E, An Y, Zoli M, Tanaka T, Simonsick EM, Kitner-Triolo MH, et al. Association Between Accelerated Multimorbidity and Age-Related Cognitive Decline in Older Baltimore Longitudinal Study of Aging Participants without Dementia. J Am Geriatr Soc. 2016;64(5):965–72. doi: 10.1111/jgs.14092 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Vassilaki M, Aakre JA, Cha RH, Kremers WK, St Sauver JL, Mielke MM, et al. Multimorbidity and Risk of Mild Cognitive Impairment. J Am Geriatr Soc. 2015;63(9):1783–90. doi: 10.1111/jgs.13612 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Quinones AR, Chen S, Nagel CL, Botoseneanu A, Allore HG, Newsom JT, et al. Trajectories of cognitive functioning in later life: Disparities by race/ethnicity, educational attainment, sex, and multimorbidity combinations. SSM Popul Health. 2022;18:101084. doi: 10.1016/j.ssmph.2022.101084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Quinones AR, Markwardt S, Thielke S, Rostant O, Vasquez E, Botoseneanu A. Prospective Disability in Different Combinations of Somatic and Mental Multimorbidity. J Gerontol A Biol Sci Med Sci. 2018;73(2):204–10. doi: 10.1093/gerona/glx100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Dove A, Marseglia A, Shang Y, Grande G, Vetrano DL, Laukka EJ, et al. Cardiometabolic multimorbidity accelerates cognitive decline and dementia progression. Alzheimers Dement. 2022: doi: 10.1002/alz.12708 [DOI] [PubMed] [Google Scholar]
  • 15.Quinones AR, McAvay GJ, Peak KD, Vander Wyk B, Allore HG. The Contribution of Chronic Conditions to Hospitalization, Skilled Nursing Facility Admission, and Death: Variation by Race. Am J Epidemiol. 2022;191(12):2014–25. doi: 10.1093/aje/kwac143 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kadambi S, Abdallah M, Loh KP. Multimorbidity, Function, and Cognition in Aging. Clin Geriatr Med. 2020;36(4):569–84. doi: 10.1016/j.cger.2020.06.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and measuring chronic conditions: imperatives for research, policy, program, and practice. Prev Chronic Dis. 2013;10:E66. doi: 10.5888/pcd10.120239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ivan CS, Seshadri S, Beiser A, Au R, Kase CS, Kelly-Hayes M, et al. Dementia after stroke: the Framingham Study. Stroke. 2004;35(6):1264–8. doi: 10.1161/01.STR.0000127810.92616.78 [DOI] [PubMed] [Google Scholar]
  • 19.Huang YY, Chen SD, Leng XY, Kuo K, Wang ZT, Cui M, et al. Post-Stroke Cognitive Impairment: Epidemiology, Risk Factors, and Management. J Alzheimers Dis. 2022;86(3):983–99. doi: 10.3233/JAD-215644 [DOI] [PubMed] [Google Scholar]
  • 20.Linnemann C, Lang UE. Pathways Connecting Late-Life Depression and Dementia. Front Pharmacol. 2020;11:279. doi: 10.3389/fphar.2020.00279 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Yang L, Deng YT, Leng Y, Ou YN, Li YZ, Chen SD, et al. Depression, Depression Treatments, and Risk of Incident Dementia: A Prospective Cohort Study of 354,313 Participants. Biol Psychiatry. 2023;93(9):802–9. doi: 10.1016/j.biopsych.2022.08.026 [DOI] [PubMed] [Google Scholar]
  • 22.de Araujo JAP, Xavier EFM, Rodrigues EDS, Machado DB, Barreto ME, Kanaan RA, et al. Main and moderated effects of multimorbidity and depressive symptoms on cognition. Braz J Psychiatry. 2022;44(6):644–9. doi: 10.47626/1516-4446-2022-2601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Scuteri A, Spazzafumo L, Cipriani L, Gianni W, Corsonello A, Cravello L, et al. Depression, hypertension, and comorbidity: disentangling their specific effect on disability and cognitive impairment in older subjects. Arch Gerontol Geriatr. 2011;52(3):253–7. doi: 10.1016/j.archger.2010.04.002 [DOI] [PubMed] [Google Scholar]
  • 24.Heeringa S, Connor, J. Technical Description of the Health and Retirement Study Sample Design: Institute for Social Research, University of Michigan; 1995. https://hrs.isr.umich.edu/publications/biblio/5310.
  • 25.Cigolle CT, Nagel CL, Blaum CS, Liang J, Quinones AR. Inconsistency in the Self-report of Chronic Diseases in Panel Surveys: Developing an Adjudication Method for the Health and Retirement Study. J Gerontol B Psychol Sci Soc Sci. 2018;73(5):901–12. doi: 10.1093/geronb/gbw063 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Weir D, Langa, KM, Ryan, LH. 2016 Harmonized Cognitive Assessment Protocol (HCAP) Study Protocol Summary Ann Arbor, MI: Health and Retirement Study, Survey Research Center, Institute for Social Research, University of Michigan; 2016. https://hrs.isr.umich.edu/publications/biblio/9950.
  • 27.Langa KM, Ryan LH, McCammon RJ, Jones RN, Manly JJ, Levine DA, et al. The Health and Retirement Study Harmonized Cognitive Assessment Protocol Project: Study Design and Methods. Neuroepidemiology. 2020;54(1):64–74. doi: 10.1159/000503004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Crimmins EM, Kim JK, Langa KM, Weir DR. Assessment of cognition using surveys and neuropsychological assessment: the Health and Retirement Study and the Aging, Demographics, and Memory Study. J Gerontol B Psychol Sci Soc Sci. 2011;66 Suppl 1:i162–71. doi: 10.1093/geronb/gbr048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kenneth M. Langa DRW, Mohammed Kabeto, Amanda Sonnega. Langa-Weir Classification of Cognitive Function (1995–2020): Institute for Social Research, University of Michigan; 2023. https://hrsdata.isr.umich.edu/data-products/langa-weir-classification-cognitive-function-1995-2020.
  • 30.Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging. 1997;12(2):277–87. doi: 10.1037//0882-7974.12.2.277 [DOI] [PubMed] [Google Scholar]
  • 31.Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1994;10(2):77–84. [PubMed] [Google Scholar]
  • 32.Steffick D. Documentation of Affective Functioning Measures in the Health and Retirement Study: Institute for Social Research, University of Michigan; 2000. https://hrs.isr.umich.edu/publications/biblio/5411.
  • 33.Defining Adult Overweight & Obesity: Centers for Disease Control and Prevention; 2022. https://www.cdc.gov/obesity/basics/adult-defining.html.
  • 34.Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab. 2014;65(2–3):205–10. doi: 10.1159/000360229 [DOI] [PubMed] [Google Scholar]
  • 35.Nagin DS. Group-Based Modeling of Development. Cambridge, MA: Harvard University Press; 2005. [Google Scholar]
  • 36.Haviland AM, Bobby Jones L., and Daniel S. Nagin. Group-based trajectory modeling extended to account for nonrandom participant attrition. Sociological Methods & Research. 2011;40(2):367–90. [Google Scholar]
  • 37.Jones BL, Nagin DS. A Stata Plugin for Estimating Group-based Trajectory Models. 2018. [Google Scholar]
  • 38.Alexopoulos GS. Vascular disease, depression, and dementia. J Am Geriatr Soc. 2003;51(8):1178–80. doi: 10.1046/j.1532-5415.2003.51373.x [DOI] [PubMed] [Google Scholar]
  • 39.Dominguez RO, Marschoff ER, Oudkerk LM, de la Ossa Angulo LE, Perez SV, Bianchi GA, et al. Neurological Disorders in an Elderly Cohort Experienced Past Stressful Events: A Retrospective-prospective Study. Curr Aging Sci. 2022;15(2):163–71. doi: 10.2174/1874609815666220118104234 [DOI] [PubMed] [Google Scholar]
  • 40.Vasquez E, Botoseneanu A, Bennett JM, Shaw BA. Racial/Ethnic Differences in Trajectories of Cognitive Function in Older Adults. J Aging Health. 2016;28(8):1382–402. doi: 10.1177/0898264315620589 [DOI] [PubMed] [Google Scholar]
  • 41.Avila JF, Renteria MA, Jones RN, Vonk JMJ, Turney I, Sol K, et al. Education differentially contributes to cognitive reserve across racial/ethnic groups. Alzheimers Dement. 2021;17(1):70–80. doi: 10.1002/alz.12176 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Zuelsdorff M, Okonkwo OC, Norton D, Barnes LL, Graham KL, Clark LR, et al. Stressful Life Events and Racial Disparities in Cognition Among Middle-Aged and Older Adults. J Alzheimers Dis. 2020;73(2):671–82. doi: 10.3233/JAD-190439 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ferraro KF, Shippee TP. Aging and cumulative inequality: how does inequality get under the skin? Gerontologist. 2009;49(3):333–43. doi: 10.1093/geront/gnp034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Zhang W, Chen Y, Chen N. Body mass index and trajectories of the cognition among Chinese middle and old-aged adults. BMC Geriatr. 2022;22(1):613. doi: 10.1186/s12877-022-03301-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Liang F, Fu J, Moore JB, Zhang X, Xu Y, Qiu N, et al. Body Mass Index, Waist Circumference, and Cognitive Decline Among Chinese Older Adults: A Nationwide Retrospective Cohort Study. Front Aging Neurosci. 2022;14:737532. doi: 10.3389/fnagi.2022.737532 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Sun Z, Wang ZT, Sun FR, Shen XN, Xu W, Ma YH, et al. Late-life obesity is a protective factor for prodromal Alzheimer’s disease: a longitudinal study. Aging (Albany NY). 2020;12(2):2005–17. doi: 10.18632/aging.102738 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Coin A, Veronese N, De Rui M, Mosele M, Bolzetta F, Girardi A, et al. Nutritional predictors of cognitive impairment severity in demented elderly patients: the key role of BMI. J Nutr Health Aging. 2012;16(6):553–6. doi: 10.1007/s12603-012-0052-x [DOI] [PubMed] [Google Scholar]
  • 48.Surrow S, Jessen-Winge C, Ilvig PM, Christensen JR. The motivation and opportunities for weight loss related to the everyday life of people with obesity: A qualitative analysis within the DO:IT study. Scand J Occup Ther. 2021;28(6):479–87. doi: 10.1080/11038128.2020.1726451 [DOI] [PubMed] [Google Scholar]
  • 49.Wu Z, Phyo AZZ, Al-Harbi T, Woods RL, Ryan J. Distinct Cognitive Trajectories in Late Life and Associated Predictors and Outcomes: A Systematic Review. J Alzheimers Dis Rep. 2020;4(1):459–78. doi: 10.3233/ADR-200232 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Hayden KM, Reed BR, Manly JJ, Tommet D, Pietrzak RH, Chelune GJ, et al. Cognitive decline in the elderly: an analysis of population heterogeneity. Age Ageing. 2011;40(6):684–9. doi: 10.1093/ageing/afr101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Howrey BT, Raji MA, Masel MM, Peek MK. Stability in Cognitive Function Over 18 Years: Prevalence and Predictors among Older Mexican Americans. Curr Alzheimer Res. 2015;12(7):614–21. doi: 10.2174/1567205012666150701102947 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Han L, Gill TM, Jones BL, Allore HG. Cognitive Aging Trajectories and Burdens of Disability, Hospitalization and Nursing Home Admission Among Community-living Older Persons. J Gerontol A Biol Sci Med Sci. 2016;71(6):766–71. doi: 10.1093/gerona/glv159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Quinones AR, Nagel CL, Botoseneanu A, Newsom JT, Dorr DA, Kaye J, et al. Multidimensional trajectories of multimorbidity, functional status, cognitive performance, and depressive symptoms among diverse groups of older adults. J Multimorb Comorb. 2022;12: doi: 10.1177/26335565221143012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Chen H, Zhou Y, Huang L, Xu X, Yuan C. Multimorbidity burden and developmental trajectory in relation to later-life dementia: A prospective study. Alzheimers Dement. 2023;19(5):2024–33. doi: 10.1002/alz.12840 [DOI] [PubMed] [Google Scholar]
  • 55.Skinner KM, Miller DR, Lincoln E, Lee A, Kazis LE. Concordance between respondent self-reports and medical records for chronic conditions: experience from the Veterans Health Study. J Ambul Care Manage. 2005;28(2):102–10. doi: 10.1097/00004479-200504000-00002 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Bruno Pereira Nunes

11 Mar 2024

PONE-D-23-40847Mental-Somatic Multimorbidity in Trajectories of Cognitive Function for Middle-Aged and Older AdultsPLOS ONE

Dear Dr. Quiñones,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The manuscript has been assessed by two reviewers. Their comments are appended below. The reviewers have raised some of minor concerns about the manuscript, and in particular they feel that some methodological issues exist that affect the technical soundness of your study, and the conclusions of the paper.

Please submit your revised manuscript by Apr 25 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Bruno Pereira Nunes, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that PLOS ONE has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, all author-generated code must be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.

3. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.  

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a high-quality manuscript. The study is novel, interesting, and carefully reported. The research question is important and the methods for testing are rigorous. I enjoyed reading this report and unreservedly recommend it be published.

I have suggestions for fairly minor revisions, focused on grammar and presentation.

Section 2.3.3. starts with a description of statistical analysis that be deleted and instead placed in Section 2.4. In its current form, it disrupts the reader's flow.

Typo in 2.4.1.- " Following established guidance [31], We began by fitting a sequence of unconditional GBTMs in order to 1)", we should be in lowercase.

Section 2.4. In its current form is a bit hard to read. You can change this by creating paragraph separations. E.g. in 2.4.2 - "Moreover, changes in multimorbidity..." should be a separate paragraph.

Excellent job at providing detailed descriptions of the methods in the Appendix section.

Section 3.2. Place the group size immediately after the group name for consistency. E.g., "Low risk with late-life increase trajectory (63.7%), represented the largest proportion of the study sample "

Section 3.5. Please re-state in sentence form "respondents with < high school education"

The discussion section is well-framed and contextualised.

Reviewer #2: The study explored associations between mental-somatic multimorbidity combinations with both high depressive symptoms and stroke and probability of cognitive impairment during adulthood. I have some comments and questions about this article:

2.2. Study Population

The authors excluded participants who reported other races like Asians, African Americans and Native Americans.

Question 1- Why exclude these participants who represent 9% of the racial composition of Oregon's population? It’s a standard amongst researchers to include all categories of race in the study’s region

2.3.3 Covariates

Question 2- Why, in this topic, wasn’t the male gender reported, only the female?

Question 3- The topic about including/excluding races was not clear (mutually exclusive categories: non-Hispanic White, non-Hispanic Black, Hispanic). Could you explain it further?

2.4. Statistical analysis

The GBTM is an appropriate model for this type of study, as it relies on data to generate latent subgroups of individuals with different health trajectories over time and, consequently, potentially differential risks of the disease. Although the statistical analysis used to estimate differences between groups has a few limitations:

- Table 1 provides detailed descriptive information on the analytic sample at baseline. The main limitation observed in this table is not presenting the percentage by rows, only by columns. Without this information, it is not possible to infer the distribution of the outcome variables between the independent variables or covariates.

Question 4- Was there a statistically significant difference between groups by sex, race, age, etc?

Question 5- For example: In table 1, among men, what is the prevalence in each of the Three distinct cognitive trajectories?

Question 6- Was there a statistically significant difference between the prevalence of men and women within the groups?

Question 7- Was there a statistically significant difference in the risk of individuals in the group without multimorbidity being included in each stage when compared to individuals with multimorbidity?

Regarding references, I suggest bringing more recent articles. 50% were more than 8 years old since its publication. There is a lot of scientific literature on multimorbidity, depressive symptoms and cognitive impairment.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 May 14;19(5):e0303599. doi: 10.1371/journal.pone.0303599.r002

Author response to Decision Letter 0


22 Apr 2024

Reviewer #1:

This is a high-quality manuscript. The study is novel, interesting, and carefully reported. The research question is important and the methods for testing are rigorous. I enjoyed reading this report and unreservedly recommend it be published. I have suggestions for fairly minor revisions, focused on grammar and presentation.

We thank the reviewer for their kind remarks.

1. Section 2.3.3. starts with a description of statistical analysis that be deleted and instead placed in Section 2.4. In its current form, it disrupts the reader's flow.

We have made this change according to the reviewer’s suggestion.

2. Typo in 2.4.1. " Following established guidance [31], We began by fitting a sequence of unconditional GBTMs in order to 1)", we should be in lowercase.

We have made this change according to the reviewer’s suggestion.

3. Section 2.4. In its current form is a bit hard to read. You can change this by creating paragraph separations. E.g. in 2.4.2 - "Moreover, changes in multimorbidity..." should be a separate paragraph. Excellent job at providing detailed descriptions of the methods in the Appendix section.

We have made this change according to the reviewer’s suggestion.

4. Section 3.2. Place the group size immediately after the group name for consistency. E.g., "Low risk with late-life increase trajectory (63.7%), represented the largest proportion of the study sample ".

We have made this change according to the reviewer’s suggestion.

5. Section 3.5. Please re-state in sentence form "respondents with < high school education"

We have revised the sentence to, “respondents with less than a high school education”.

Reviewer #2

The study explored associations between mental-somatic multimorbidity combinations with both high depressive symptoms and stroke and probability of cognitive impairment during adulthood. I have some comments and questions about this article:

2.2. Study Population

1. The authors excluded participants who reported other races like Asians, African Americans and Native Americans. Why exclude these participants who represent 9% of the racial composition of Oregon's population? It’s a standard amongst researchers to include all categories of race in the study’s region.

We agree with the reviewer’s point regarding the importance of inclusivity and diversity in research. However, we opted not to include “other” race category in our analytic sample because the publicly available race category includes a highly heterogeneous composition of study participants, including American Indian, Alaskan Native, Asian, Native Hawaiian, and Pacific Islander, and any other races, rendering any differences of this category difficult to interpret. As a result, we decided to include mutually exclusive categories (for Non-Hispanic White, Non-Hispanic Black and Hispanic) in our analyses, and provide further details and explanation regarding how racial/ethnic categories were constructed. We also note this as a limitation to our work and call for future work to examine mental-somatic multimorbidity among underrepresented racial and ethnic groups with data that facilitate this line of inquiry: “Finally, while it is imperative to study multimorbidity in diverse samples of adults, we were limited by the number of racial and ethnic categories assessed in the HRS. Future studies should examine the risk of dementia associated with mental and somatic multimorbidity changes among even broader numbers of underrepresented racial and ethnic groups using data sources that facilitate these analyses (pg. 21).”

2.3.3. Covariates

2. Why, in this topic, wasn’t the male gender reported, only the female?

We have included descriptive information for male sex in Table 1 and made the change in 2.3.3 Covariates and 3.1. Sample characteristics.

3. The topic about including/excluding races was not clear (mutually exclusive categories: non-Hispanic White, non-Hispanic Black, Hispanic). Could you explain it further?

We have provided an additional brief explanation of race/ethnicity category in 2.3.3 Covariates. The race/ethnicity was defined according to the respondent’s answers to the following questions: 1) “Do you consider yourself Hispanic or Latino?” and 2) “Do you consider yourself primarily white or Caucasian, Black or African American, American Indian, or Asian, or something else?” The answer to the first question was prioritized, which means self-identification of Hispanic (or Latino) was given precedence over any other racial categories and the respondent would be categorized as Hispanic (or Latino) if the study participant answered “yes”. If the respondents didn’t consider themselves as Hispanic or Latino (answered “No” for the first question), they were categorized into Non-Hispanic White or Non-Hispanic Black based on their answers to the second question - white or Caucasian, or, Black or African American. We have provided a table in the attached response letter showing how the mutually exclusive racial/ethnic categories were constructed.

2.4. Statistical analysis

The GBTM is an appropriate model for this type of study, as it relies on data to generate latent subgroups of individuals with different health trajectories over time and, consequently, potentially differential risks of the disease. Although the statistical analysis used to estimate differences between groups has a few limitations:

Table 1 provides detailed descriptive information on the analytic sample at baseline. The main limitation observed in this table is not presenting the percentage by rows, only by columns. Without this information, it is not possible to infer the distribution of the outcome variables between the independent variables or covariates.

We have provided an additional table as S1 Table in S1 Appendix presenting the distribution of the trajectory groups by levels of independent variables and covariates. We performed additional statistical tests for comparisons and added the results to the table as well. The table was also provided in the attached response letter.

While we agree with the reviewer that the trajectory group is the main outcome variable in our multinomial regression analysis and it can provide additional information to present the distribution of trajectory groups by levels of covariates (the table shown above), one of our primary aims of presenting the distribution of sociodemographic and health-related covariates (e.g. racial/ethnicity, education, wealth, etc.) by trajectory groups in Table 1 is to show differences in the proportions of racial/ethnic minoritized groups and socioeconomic characteristics by the different trajectory groups. In this way we provide additional descriptive information prior to presenting results from the analyses. Therefore, we opted to keep Table 1 formatted as is in the manuscript but did add one additional column to present the results from statistical tests comparing the groups. We have also added relevant description of statistical tests in 2.4.3 in Statistical Analysis section. We have provided an additional table as S1 Table in S1 Appendix presenting the distribution of the trajectory groups by levels of independent variables and covariates. However, if the Editor/Reviewer prefers that S1 Table be in the manuscript we are willing to change them.

4. Was there a statistically significant difference between groups by sex, race, age, etc.?

There were statistically significant differences between groups in terms of sex (p<0.01), race (p<0.01) and age (p<0.01). We have performed the statistical tests and presented the results in both Table 1 in the manuscript and Table S1 in S1 Appendix.

5. For example, in table 1, among men, what is the prevalence in each of the three distinct cognitive trajectories?

Among men, 61.3% were in the Low risk with late-life increase group, 26.1% in the Low initial risk with rapid increase group, and 12.7% in the High risk group. The information is in Table S1 in S1 Appendix.

6. Was there a statistically significant difference between the prevalence of men and women within the groups?

We have performed the statistical tests and there was a statistically significant difference in male and female prevalence within the groups (p<0.01).

7. Was there a statistically significant difference in the risk of individuals in the group without multimorbidity being included in each stage when compared to individuals with multimorbidity?

We included a table in the attached response letter showing the distribution of No multimorbidity and Multimorbidity (collapsing all four multimorbidity categories) at baseline. We performed additional statistical tests to compare between No multimorbidity with Multimorbidity at baseline: the proportion of individuals with multimorbidity at baseline is higher in the High risk group (14.1% vs. 9.9%, p<0.01) and in the Low initial risk with rapid increase group (30.0% vs. 22.2%, p<0.01) when compared with individuals without multimorbidity at baseline.

Additionally, we performed a multinomial regression analysis including baseline multimorbidity (yes or no) as an independent variable while adjusting for other covariates. This additional analysis shows that individuals with multimorbidity at baseline had a higher probability of being included in the Low initial risk with rapid increase group (OR:1.19, 95%CI: 1.11,1.28) and High risk group (OR:1.12, 95%CI: 1.01, 1.25) when compared with individuals with no multimorbidity at baseline. However, we opted not to include a binary variable for multimorbidity at baseline, as our analyses are not cross-sectional; thus, extended beyond this specification by examining the time-varying nature of multimorbidity on the probability of cognitive impairment over time with age as the time scale. As a result, we include multimorbidity in the group-based trajectory model as a changing category which was not static over time for individuals to account for its association with cognitive impairment probability within each trajectory, rather than include a one-time measurement of baseline multimorbidity to predict the group membership.

8. Regarding references, I suggest bringing more recent articles. 50% were more than 8 years old since its publication. There is a lot of scientific literature on multimorbidity, depressive symptoms and cognitive impairment.

In addition to some foundational references initially included, we added more recent literature in the citations for the manuscript to update the introduction and discussion and bring more updated findings to our presentation of the topic:

1. Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The Epidemiology of Alzheimer's Disease Modifiable Risk Factors and Prevention. J Prev Alzheimers Dis. 2021;8(3):313-21

2. Kadambi S, Abdallah M, Loh KP. Multimorbidity, Function, and Cognition in Aging. Clin Geriatr Med. 2020;36(4):569-84.

3. Huang YY, Chen SD, Leng XY, Kuo K, Wang ZT, Cui M, et al. Post-Stroke Cognitive Impairment: Epidemiology, Risk Factors, and Management. J Alzheimers Dis. 2022;86(3):983-99

4. Yang L, Deng YT, Leng Y, Ou YN, Li YZ, Chen SD, et al. Depression, Depression Treatments, and Risk of Incident Dementia: A Prospective Cohort Study of 354,313 Participants. Biol Psychiatry. 2023;93(9):802-9

5. Quinones AR, Nagel CL, Botoseneanu A, Newsom JT, Dorr DA, Kaye J, et al. Multidimensional trajectories of multimorbidity, functional status, cognitive performance, and depressive symptoms among diverse groups of older adults. J Multimorb Comorb. 2022;12:doi: 10.1177/26335565221143012

Attachment

Submitted filename: PLOS_Response to reviewers_R1_final.docx

pone.0303599.s003.docx (44KB, docx)

Decision Letter 1

Bruno Pereira Nunes

29 Apr 2024

Mental-Somatic Multimorbidity in Trajectories of Cognitive Function for Middle-Aged and Older Adults

PONE-D-23-40847R1

Dear Dr. Quiñones,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Bruno Pereira Nunes, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Bruno Pereira Nunes

2 May 2024

PONE-D-23-40847R1

PLOS ONE

Dear Dr. Quiñones,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Bruno Pereira Nunes

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. Comprehensive analysis documentation.

    (DOCX)

    pone.0303599.s001.docx (194.9KB, docx)
    S2 Appendix. Technical details and reproducible codes for visualization of cognitive impairment trajectories with multimorbidity transition.

    (DOCX)

    pone.0303599.s002.docx (24KB, docx)
    Attachment

    Submitted filename: PLOS_Response to reviewers_R1_final.docx

    pone.0303599.s003.docx (44KB, docx)

    Data Availability Statement

    The data underlying the results presented in this study are publicly available from the Health and Retirement Study, http://hrsonline.isr.umich.edu/. All analytic data files are available from the Figshare database (accession number(s) https://doi.org/10.6084/m9.figshare.25631778.v1).


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES